IP Library Granted Patent US 10,934,598
Granted Patent B2
US 10,934,598 · App. 16/013,502 · Granted Mar 2, 2021

Assay for detection of human parvovirus nucleic acid

Inventor: James M. Carrick (Lanham, MD)
Assignee: GEN-PROBE INCORPORATED
C12Q1/701C12Q1/702C12Q1/686C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,934,598
App. No.
16/013,502
Granted
Mar 2, 2021
Kind
B2
Abstract

Nucleic acid oligomers specific for human parvovirus genomic DNA are disclosed. An assay for amplifying and detecting human parvovirus genotypes 1, 2 and 3 nucleic acid in biological specimens is disclosed. Compositions for amplifying and detecting the presence of human parvovirus genotypes 1, 2 and 3 genomic DNA in human biological specimens are disclosed.

Claims (44)

1. A method for the detection of human parvovirus from a sample comprising the steps of:

a) obtaining a sample suspected of containing human parvovirus genotype 1, genotype 2, or genotype 3;

b) contacting the sample with an amplification oligomer combination comprising:

i) at least one primer oligomer member comprising a target-binding sequence that is SEQ ID NO:48 or SEQ ID NO:50;

ii) a first promoter-based oligomer member that is SEQ ID NO:73; and

iii) a second promoter-based oligomer member that is SEQ ID NO:78;

c) performing an isothermal amplification reaction on the sample to generate an amplicon from a human parvovirus in the sample or from an amplicon thereof; and

d) detecting the amplicon with a detection probe oligomer; wherein the presence of an amplicon as determined by the detecting step indicates that one or more of human parvovirus genotypes 1, 2 and 3 are present in the sample.

2. The method of claim 1 , wherein the at least one primer oligomer member comprises the target-binding sequence that is SEQ ID NO:50.

3. The method of claim 1 , wherein the at least one primer oligomer member comprises the target-binding sequence that is SEQ ID NO:48.

4. The method of claim 3 , wherein the at least one primer oligomer member is SEQ ID NO:47.

5. The method of claim 1 , wherein the at least one primer oligomer member comprises a 5′ tag sequence.

6. The method of claim 1 , wherein the at least one primer member is selected from the group consisting of SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and combinations thereof.

7. The method of claim 1 , wherein the detection probe oligomer is selected from the group consisting of SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:46.

8. The method of claim 1 , further comprising the step of contacting the sample with a target capture oligomer.

9. The method of claim 8 , wherein the target capture oligomer comprises a 3′ tail portion and a target-binding sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:53, and combinations thereof.

10. The method of claim 9 , wherein the target capture oligomer is SEQ ID NO:52.

11. A method for the detection of human parvovirus from a sample comprising the steps of:

a) obtaining a sample suspected of containing human parvovirus genotype 1, genotype 2, or genotype 3;

b) contacting the sample with an amplification oligomer combination comprising at least one primer oligomer member and at least one promoter-based oligomer member, wherein the at least one primer oligomer member and the at least one promoter-based oligomer member hybridize to opposing strands of a human parvovirus genotype 1, 2 or 3 nucleic acid or amplicon thereof for transcription mediated amplification of the target nucleic acid or amplicon thereof between the hybridized primer and promoter-based oligomer members, wherein the at least one promoter-based oligomer member is a first promoter-based oligomer member that is SEQ ID NO:76 and a second promoter-based oligomer member that is SEQ ID NO:81;

c) performing an isothermal amplification reaction on the sample to generate an amplicon from a human parvovirus in the sample or from an amplicon thereof; and

d) detecting the amplicon with a detection probe oligomer; wherein the presence of an amplicon as determined by the detecting step indicates that one or more of human parvovirus genotypes 1, 2 and 3 are present in the sample.

12. The method of claim 11 , wherein the detection probe oligomer is selected from the group consisting of SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:46.

13. The method of claim 11 , further comprising the step of contacting the sample with a target capture oligomer.

14. The method of claim 13 , wherein the target capture oligomer comprises a 3′ tail portion and a target-binding sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:53, and combinations thereof.

15. A method for the detection of human parvovirus from a sample comprising the steps of:

a) obtaining a sample suspected of containing human parvovirus genotype 1, genotype 2, or genotype 3;

b) contacting the sample with an amplification oligomer combination comprising at least one primer oligomer member and at least one promoter-based oligomer member, wherein the at least one primer oligomer member and the at least one promoter-based oligomer member hybridize to opposing strands of a human parvovirus genotype 1, 2 or 3 nucleic acid or amplicon thereof for transcription mediated amplification of the target nucleic acid or amplicon thereof between the hybridized primer and promoter-based oligomer members, wherein

i) the at least one promoter-based oligomer member is selected from the group consisting of SEQ ID NOS:58, 63, 67, 68, 73, 78, 82, and combinations thereof; or

ii) the at least one primer oligomer member is SEQ ID NO:47 and the at least one promoter-based oligomer member is selected from the group consisting of SEQ ID NOs:73, 76, 78, 81, and combinations thereof;

c) performing an isothermal amplification reaction on the sample to generate an amplicon from a human parvovirus in the sample or from an amplicon thereof; and

d) detecting the amplicon with a detection probe oligomer; wherein the presence of an amplicon as determined by the detecting step indicates that one or more of human parvovirus genotypes 1, 2 and 3 are present in the sample.

16. The method of claim 15 , wherein the detection probe oligomer is selected from the group consisting of SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:46.

17. The method of claim 15 , further comprising the step of contacting the sample with a target capture oligomer.

18. The method of claim 17 , wherein the target capture oligomer comprises a 3′ tail portion and a target-binding sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:53, and combinations thereof.

19. A method for the detection of human parvovirus from a sample comprising the steps of:

a) obtaining a sample suspected of containing human parvovirus genotype 1, genotype 2, or genotype 3;

b) contacting the sample with an amplification oligomer combination comprising:

i) at least one primer oligomer member that is SEQ ID NO:47;

ii) a first promoter-based oligomer member comprising a target binding sequence that is SEQ ID NO:75; and

iii) a second promoter-based oligomer member comprising a target binding sequence that is SEQ ID NO:80;

wherein the target binding sequence of each of the first and second promoter-based oligomer members is joined at its 5′ end to a promoter sequence;

c) performing an isothermal amplification reaction on the sample to generate an amplicon from a human parvovirus in the sample or from an amplicon thereof; and

d) detecting the amplicon with a detection probe oligomer; wherein the presence of an amplicon as determined by the detecting step indicates that one or more of human parvovirus genotypes 1, 2 and 3 are present in the sample.

Assignments (5)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 12, 2021
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 057787/0526 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME CORRECTION FROM INCORPORATED, GEN-PROBE, INCO TO GEN-PROBE INCORPORATED PREVIOUSLY RECORDED AT REEL: 054381 FRAME: 0587. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 20, 2020
From: CARRICK, JAMES M
To: GEN-PROBE INCORPORATED
Reel/Frame 054485/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2020
From: CARRICK, JAMES M.
To: INCORPORATED GEN-PROBE
Reel/Frame 054381/0587 →
SECURITY INTEREST Recorded Oct 19, 2018
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED; CYNOSURE, INC.; FAXITRON BIOPTICS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047272/0347 →
Continuity (4)
Division 14569338 · Dec 12, 2014
Continuation 13203715
Provisional Application 61155685 · Feb 26, 2009
Related Publication 20180347000A1 · Dec 6, 2018